Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADC Agree

Closed 01-10 16:00:00 EST

68.36

-1.33

-1.91%

盘后68.36

+0.000.00%

16:41 EST

High68.99	Low67.58	Vol761.67K
Open68.48	D1 Closing69.69	Amplitude2.02%
Mkt Cap7.45B	Tradable Cap7.31B	Total Shares109.00M
T/O52.13M	T/O Rate0.71%	Tradable Shares107.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"Agree","latestPrice":68.36,"timestamp":1736542800000,"preClose":69.69,"halted":0,"volume":761667,"hourTrading":{"tag":"盘后","latestPrice":68.36,"preClose":68.36,"latestTime":"16:41 EST","volume":22893,"amount":1564959.01,"timestamp":1736545310724},"delay":0,"floatShares":107000000,"shares":109000000,"eps":1.809026,"marketStatus":"Closed","change":-1.33,"latestTime":"01-10 16:00:00 EST","open":68.48,"high":68.99,"low":67.58,"amount":52130012.813999996,"amplitude":0.020232,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.809026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736758800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":69.69,"dividendRate":0.043622,"preHourTrading":{"tag":"盘前","latestPrice":68.93,"preClose":69.69,"latestTime":"09:26 EST","volume":111,"amount":7651.68954,"timestamp":1736519212259},"postHourTrading":{"tag":"盘后","latestPrice":68.36,"preClose":68.36,"latestTime":"16:41 EST","volume":22893,"amount":1564959.01,"timestamp":1736545310724},"volumeRatio":0.593827,"impliedVol":0.2432,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/ADC/tweets","defaultTab":"tweets","newsList":[{"id":"2502886357","title":"NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2502886357","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502886357?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:05","pubTimestamp":1736514300,"startTime":"0","endTime":"0","summary":"BELTSVILLE, Md., Jan. 10, 2025  -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate  as a therapeutic for treating multiple cancers.“Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextCure as we continue to advance our B7-H4 ADC program,” said Udayan Guha, M.D., Ph.D., NextCure’s Senior Vice President, Clinical & Translational Development. “We look forward to establishing the safety, tolerability, and preliminary anti-tumor activity of LNCB74. We believe this novel ADC could potentially transform treatment options for multiple cancers.”In December 2024, NextCure announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for LNCB74.LNCB74 is being developed in partne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nextcure-announces-first-patient-dosed-130500118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4139","ADC","NXTC","BK4080"],"gpt_icon":0},{"id":"2502111857","title":"Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2502111857","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502111857?lang=en_us&edition=fundamental","pubTime":"2025-01-10 19:45","pubTimestamp":1736509500,"startTime":"0","endTime":"0","summary":"Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor. If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population. Treatment nave high-risk NMIBC is an area of significant unmet need, where therapeutic options have largely remained unchanged for over three decades. NEW YORK, January 10, 2025----Pfizer Inc.  today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody , in combination with Bacillus Calmette-Guérin  as induction therapy with or without maintenance in patients with BCG-nave, high-risk non-muscle invasive bladder cancer . The study met its primary endpoint of event-free survival  by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-bcg-improves-114500774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985481810.HKD","SG9999001176.USD","LU0289739699.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","BK4599","SG9999003800.SGD","SG9999002224.SGD","BK4550","LU0058720904.USD","BK4588","IE0002270589.USD","ADC","LU0456855351.SGD","BK4533","BK4007","SG9999011175.SGD","LU1883839398.USD","LU1894683264.USD","BK4581","IE00B19Z3B42.SGD","BK4135","BK4592","LU1066051498.USD","LU1057294990.SGD","PFE","LU0170899867.USD","IE00BLSP4239.USD","LU0868494617.USD","LU1894683348.USD","IE00B19Z3581.USD","LU1023059063.AUD","BK4585","BCG","LU0234572021.USD","LU0321505439.SGD","IE00BLSP4452.SGD","LU0122379950.USD","SG9999013999.USD","BK4080","LU1066053197.SGD","LU0306807586.USD","LU0321505868.SGD","LU0306806265.USD","LU0225284248.USD","BK4534","BK4568","SG9999002232.USD","LU0225771236.USD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2502378788","title":"Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2502378788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502378788?lang=en_us&edition=fundamental","pubTime":"2025-01-10 17:39","pubTimestamp":1736501995,"startTime":"0","endTime":"0","summary":"Innate Pharma (IPHA) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases.The company said it is currently te","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHA","BK4568","LU0109394709.USD","BK4585","IPHYF","BK4231","ADC","BK4139","AZN","LU2456880835.USD","LU2236285917.USD","LU0889565916.HKD","LU2417539215.USD","BK4007","AAQC","LU2462157665.USD","LU1829250122.USD","LU0320765992.SGD","BK4588","BK4080"],"gpt_icon":0},{"id":"2502884619","title":"Innate Pharma Announces Transformative Strategy to Accelerate Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2502884619","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502884619?lang=en_us&edition=fundamental","pubTime":"2025-01-10 14:00","pubTimestamp":1736488800,"startTime":"0","endTime":"0","summary":"Strategy anchored on early clinical development of proprietary assets with single-agent potential:. Drive innovation with first-in-class ANKET NK-cell engager Platform. Innate Pharma SA   today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide.\"Our updated strategy underscores Innate Pharma’s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide,\" said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. \"With a focus on our ANKET platform and ADC programs, we are poised to redefine the landscape of immunotherapy, addressing unmet needs in oncology and autoimmune diseases. This roadmap reflects our steadfast commitment to advancing science, strengthening partnerships, and maximizing value for patients and shareholders alike as we look toward a br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-announces-transformative-strategy-060000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","IPHYF","IPHA","AAQC","BK4080","BK4139","BK4231"],"gpt_icon":0},{"id":"2502072716","title":"Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2502072716","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502072716?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:57","pubTimestamp":1736470660,"startTime":"0","endTime":"0","summary":"Samsung Biologics  extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate  services at its new ADC facility, the South Korean biotechnology firm said Thursday.The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK7095","ADC","BK4231","ADC.AU"],"gpt_icon":0},{"id":"2502418076","title":"Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2502418076","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502418076?lang=en_us&edition=fundamental","pubTime":"2025-01-10 07:30","pubTimestamp":1736465400,"startTime":"0","endTime":"0","summary":"SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass., January 09, 2025----Zai Lab Limited  today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics  Co., Ltd.  to use MediLink’s TMALIN antibody-drug conjugate  platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.\"MediLink has built a differentiated proprietary ADC technology platform, and we are excited to broaden our global partnership,\" said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. \"Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and enriches our global oncology pipeline to address unmet medical needs. We look forward to working with MediLink to advance this compound into the clinic soon.\". \"Zai Lab’s strong commitment to innovation and proven track record of glob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-announces-strategic-partnership-233000067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1023057109.AUD","BK4585","IE00B12V2V27.USD","LU2039709279.SGD","LU0359201612.USD","IE00BYTNYN87.SGD","LU0359202008.SGD","01698","BK4535","BK4563","BK4108","BK4509","BK4080","BK4548","BK4571","ADC","BK4565","IE00BYQNZ168.SGD","BK4531","ZLAB","BK4139","SG9999011746.SGD","LENZ","TME","BK4588","BK4552","BK4231","BK4526"],"gpt_icon":0},{"id":"2502044130","title":"Micron Stock Is Up 18% This Year. Analysts Can't Agree on What's Next. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2502044130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502044130?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:48","pubTimestamp":1736441280,"startTime":"0","endTime":"0","summary":"Micron Technology stock is the top performer in the S&P 500 this year, and while analysts are generally optimistic about its performance, some have lingering doubts.Shares of the memory and storage company were up over 18% this year through Wednesday's close, while the index itself had gained only 0.6%.The stock rose 2.7% to $101.91 on Monday after Nvidia CEO Jensen Huang said that Micron was providing memory for the graphics-processing units of the company's RTX 50 videogame chips.The mean rating on the stock among the nearly 30 analysts tracked by FactSet who follow the company is Overweight. The average price target is $131.47.The biggest bull is Rosenblatt Securities analyst Hans Mosesmann, with a Buy rating and $250 price target on the shares.Mosesmann's enthusiasm is nothing new. He reiterated a $225 price target in June, saying Micron was set to capitalize on \"one of the largest memory cycles in history.\". Micron was also included in New Street Research's tech stock picks for 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4141","BK4080","BK4533","LU0157215616.USD","LU2360106780.USD","HBM","BK4527","ADC","LU0889566641.SGD","LU2048586759.USD","MU","BK4588","LU2211815571.USD","LU1852331112.SGD","LU2286300806.USD","BK4566","BK4512","BK4554","LU0792757196.USD","BK4168","LU2250418816.HKD","LU0642271901.SGD","LU1366333091.USD","BK4553","GB00BDT5M118.USD","IE00B19Z3B42.SGD","LU0081259029.USD","LU0082616367.USD","BK4532","LU0056508442.USD","LU0127658192.USD","IE00B19Z3581.USD","BK4579","BK4231","LU0719512351.SGD","LU1316542783.SGD","IE0002270589.USD","BK4575","IE00B7SZLL34.SGD","LU1267930813.SGD"],"gpt_icon":1},{"id":"2502701176","title":"Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2502701176","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502701176?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:00","pubTimestamp":1736427600,"startTime":"0","endTime":"0","summary":"AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ --Boehringer Ingelheim and Synaffix B.V. , a Lonza company  focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates , today announced that Boehringer has licensed Synaffix's ADC technology. This new partnership significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer.ADCs are a cutting-edge class of cancer treatments that combine the targeting ability of antibodies with the potent cancer-killing power of drugs. This allows for the precise delivery of therapeutic agents directly to cancer cells, minimizing damage to healthy tissue and enhancing treatment efficacy.Peter van de Sande, Head of Synaffix, said:\"Boehringer Ingelheim is a leader in oncology treatment development, and the selection of our ADC technologies to further","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/boehringer-ingelheim-broadens-oncology-portfolio-130000913.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/boehringer-ingelheim-broadens-oncology-portfolio-130000913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LZAGF","LZAGY","ADC","BK4121","BK4231","BK4080"],"gpt_icon":0},{"id":"2502115740","title":"Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2502115740","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502115740?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:00","pubTimestamp":1736427600,"startTime":"0","endTime":"0","summary":"License agreement centered around development of a single ADC program. Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement. AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. , a Lonza company  focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates  with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation , the pharma arm of Mitsubishi Chemical Group .Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.Peter van de Sande, Head of Synaffix, said:\"This latest licensing deal with MTPC highlights the appeal of our industry-leading ADC technology offering. MTPC is a key collaborator for us, expanding our presence in the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_sg","url":"https://finance.yahoo.com/news/synaffix-mitsubishi-tanabe-pharma-sign-130000514.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/synaffix-mitsubishi-tanabe-pharma-sign-130000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_sg","symbols":["BK4080","O6Z.SI","BK4231","BK6506","LZAGY","LZAGF","ADC"],"gpt_icon":0},{"id":"2502083564","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083564?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:05","pubTimestamp":1736370300,"startTime":"0","endTime":"0","summary":"Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006667/0/en/Zymeworks-Outlines-Strategic-Priorities-and-Outlook-for-2025-and-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4080","BTC"],"gpt_icon":0},{"id":"2501775287","title":"China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type","url":"https://stock-news.laohu8.com/highlight/detail?id=2501775287","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501775287?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:58","pubTimestamp":1736348280,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, Jan.  08, 2025  (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 Januar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006388/0/en/China-Medical-System-00867-Obtained-New-Drug-ZUNVEYL-for-the-Treatment-of-Mild-to-Moderate-Dementia-of-the-Alzheimer-s-Type.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYV24P56.USD","ADC","BK4080","SG9999015952.SGD","BK4231","SG9999015978.USD","LU2488822045.USD","00867","IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015945.SGD","SG9999015986.USD","BK1593","BK1191"],"gpt_icon":0},{"id":"2501724538","title":"Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724538","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501724538?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., Jan.  08, 2025  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its first-in-human dose escalation clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006205/0/en/Corbus-Pharmaceuticals-Announces-that-Clinical-Data-for-CRB-701-from-Western-Dose-Escalation-Study-to-be-Presented-at-ASCO-GU-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4139","WRN","BK4168","CRBP","BK4080"],"gpt_icon":0},{"id":"2501721896","title":"Agree Realty price target lowered to $74 from $80 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2501721896","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501721896?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:56","pubTimestamp":1736340985,"startTime":"0","endTime":"0","summary":"Mizuho lowered the firm’s price target on Agree Realty (ADC) to $74 from $80 and keeps a Neutral rating on the shares as part of a 2025 real estate...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agree-realty-price-target-lowered-to-74-from-80-at-mizuho?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agree-realty-price-target-lowered-to-74-from-80-at-mizuho?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","ADC"],"gpt_icon":0},{"id":"2501729573","title":"Agree Realty price target lowered to $79 from $80 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2501729573","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501729573?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:25","pubTimestamp":1736339117,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brad Heffern lowered the firm’s price target on Agree Realty  to $79 from $80 and keeps an Outperform rating on the shares after its 2025 investment volume update. RBC notes that 2024 acquisition volumes came in slightly above guidance and the firm’s estimate while the cap rate was in line, but 2025 investment volume guidance is about 10% below its prior estimate, though Agree Realty typically starts the year conservatively and works the guidance higher, the analyst tells investors in a research note. Higher cost of capital is reducing the firm’s FY26 FFO view by 3c to $4.56, RBC adds.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Agree Realty Projects Strong Investment Growth for 2025. Agree Realty price target lowered to $80 from $82 at Evercore ISI. Agree Realty downgraded to Market Perform from Outperform at JMP Securities","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/agree-realty-price-target-lowered-122517734.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agree-realty-price-target-lowered-122517734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC"],"gpt_icon":0},{"id":"2501728577","title":"Agree Realty Corp : Mizuho Cuts Target Price to $74 From $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2501728577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501728577?lang=en_us&edition=fundamental","pubTime":"2025-01-08 19:40","pubTimestamp":1736336423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O409U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2501425067","title":"Agree Realty’s Robust Growth Strategy and Financial Health Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2501425067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501425067?lang=en_us&edition=fundamental","pubTime":"2025-01-08 18:48","pubTimestamp":1736333310,"startTime":"0","endTime":"0","summary":"Analyst Ronald Kamdem from Morgan Stanley maintained a Buy rating on Agree Realty (ADC – Research Report) and keeping the price target at $75.00. R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agree-realtys-robust-growth-strategy-and-financial-health-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agree-realtys-robust-growth-strategy-and-financial-health-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC"],"gpt_icon":0},{"id":"2501742284","title":"China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501742284","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501742284?lang=en_us&edition=fundamental","pubTime":"2025-01-08 17:55","pubTimestamp":1736330100,"startTime":"0","endTime":"0","summary":"- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years1. - NMPA approval based on the global Phase 3 EV-302 trial  where the treatment combination significantly improved overall survival and progression-free survival outcomes1. TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced that China's National Medical Products Administration  has approved PADCEV in combination with KEYTRUDA  for adult patients with locally advanced or metastatic urothelial cancer . The treatment combination willprovide a new therapeutic option to patients with la/mUC in Chinaand offer an alternative to platinum-containing chemotherapy, the standard of care for nearly 40 years.1. Professor Huang Jian, Lead Primary Investigator of the EV-302 Study in China, Chairman of the Urology Subcommittee of the Chinese Medical Association, Depart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","LU1291159041.SGD","SG9999003800.SGD","IE00B3PB1722.GBP","LU1244550577.SGD","SG9999015341.SGD","LU1894683264.USD","LU0306807586.USD","OS","BK4579","ALPMY","LU1093756168.USD","BK4599","LU2506952097.USD","LU1917777945.USD","LU2361044865.SGD","IE00B19Z3B42.SGD","LU0965509010.AUD","SG9999014567.USD","LU0942090050.USD","LU0950375773.USD","LU0985481810.HKD","NHLD","LU1066051811.HKD","IE00BSNM7G36.USD","MRK","PFE","LU1941712348.USD","ADC","LU0203345920.USD","SG9999014542.SGD","LU0306806265.USD","BK4550","LU0965509101.SGD","LU1989772923.USD","SG9999001440.SGD","IE0002141913.USD","LU0320765489.SGD","LU0265550359.USD","AEIS","SG9999001176.SGD","LU1037948897.HKD","ALPMF","IE00BVYPNV92.GBP","IE0009355771.USD","LU2237443382.USD","BK4097","LU2112291526.USD","PFS","IE00BFMHRM44.USD","CSCO"],"gpt_icon":1},{"id":"2501749718","title":"JMP Securities Reaffirms Their Hold Rating on Agree Realty (ADC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501749718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501749718?lang=en_us&edition=fundamental","pubTime":"2025-01-08 14:35","pubTimestamp":1736318153,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Mitchell Germain from JMP Securities maintained a Hold rating on Agree Realty (ADC – Research Report). The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-hold-rating-on-agree-realty-adc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-hold-rating-on-agree-realty-adc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","ADC"],"gpt_icon":0},{"id":"2501576471","title":"China, US Agree on Maintaining Communication","url":"https://stock-news.laohu8.com/highlight/detail?id=2501576471","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501576471?lang=en_us&edition=fundamental","pubTime":"2025-01-08 10:22","pubTimestamp":1736302929,"startTime":"0","endTime":"0","summary":"The two lead persons for economic and trade affairs between the US and China held a virtual meeting to discuss macroeconomic developments in both countries.The call between US Secretary of the Treasury Janet Yellen, and Vice Premier He Lifeng of China was \"candid, in-depth, and constructive\" with both parties agreeing on the importance of communication and contact, the US Department of Treasury said Monday.The US side expressed concerns related to China's industrial overcapacity as well as \"malicious\" cyber activity and its impact on bilateral relationship.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US6M.BOND","US30Y.BOND","BK4231","ADC","US7Y.BOND","US10Y.BOND","BK4080","US3Y.BOND","US12M.BOND","US2Y.BOND","US5Y.BOND"],"gpt_icon":0},{"id":"2501730347","title":"Agree Realty Announces Fourth Quarter 2024 Earnings Release Date and Conference Call Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2501730347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501730347?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:05","pubTimestamp":1736283903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA45SFY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0641},{"period":"3month","weight":-0.0487},{"period":"6month","weight":0.0862},{"period":"1year","weight":0.0966},{"period":"ytd","weight":-0.0108}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agree Realty Corporation (the Company), a Maryland corporation, is a fully integrated real estate investment trust (REIT) primarily focused on the ownership, acquisition, development and management of retail properties net leased to industry leading tenants. The Company was founded in 1971 by its current Executive Chairman, Richard Agree, and its common stock was listed on the New York Stock Exchange in 1994. As of March 31, 2024, the Company owned 2,161 properties, with a total gross leasable area (GLA) of approximately 44.9 million square feet.","yearOnYearQuotes":[{"month":1,"riseRate":0.548387,"avgChangeRate":-0.005103},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.024183},{"month":8,"riseRate":0.451613,"avgChangeRate":0.001804},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005771},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.001244},{"month":11,"riseRate":0.645161,"avgChangeRate":0.002723},{"month":12,"riseRate":0.483871,"avgChangeRate":0.011628}],"exchange":"NYSE","name":"Agree","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agree,ADC,Agree股票,Agree股票老虎,Agree股票老虎国际,Agree行情,Agree股票行情,Agree股价,Agree股市,Agree股票价格,Agree股票交易,Agree股票购买,Agree股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction